Respira Therapeutics, Inc. Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

Respira Therapeutics is a small biotechnology company focused on inhaled therapeutics for cardiopulmonary diseases, with the goal of improving drug delivery to the small airways of the lung. It combines proprietary dry-powder inhaler device technologies with advanced particle-engineering-based drug formulations to place the medication where it is needed in the lung and lung periphery rather than the oropharyngeal cavity. The company’s lead candidate, RT234-PAH, has received FDA Orphan Drug Designation for Pulmonary Arterial Hypertension and is in Phase 2 trials as a first-in-class inhaled therapy for as-needed relief of PAH symptoms.

Based in Palo Alto, California, Respira operates with a small team pursuing development of inhaled therapies for PAH and other cardiopulmonary diseases. In May 2025, Respira presented late-breaking Phase 2b RT234 PAH trial results at the American Thoracic Society International Conference (ATS 2025).

Get verified Respira Therapeutics, Inc. emails free

Company overview Employee directory